What does Eqwal Stomacare do?

Eqwal Stomacare is a specialist medical practice in Gent. Private Limited, started on 18 October 2012, 1 establishment.

What is the address of Eqwal Stomacare?

The registered office of Eqwal Stomacare is located at Herman Teirlinckstraat 15, 9041 Gent.

Is Eqwal Stomacare still active?

Yes. According to the CBE (29 October 2026) Eqwal Stomacare is active, legal situation “Normale toestand”, started on 18 October 2012.

Is Eqwal Stomacare registered on Peppol?

Yes, Eqwal Stomacare is registered on the Peppol network with ID 0208:0849873517.

What is the enterprise number of Eqwal Stomacare?

The enterprise number of Eqwal Stomacare is BE0849873517.

When was Eqwal Stomacare founded?

Eqwal Stomacare was founded on 18 October 2012.

Who are the directors of Eqwal Stomacare?

According to the 2025 annual accounts, the directors of Eqwal Stomacare are: FINICOMA BV.

Is Eqwal Stomacare a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 October 2012; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Eqwal Stomacare make in 2025?

Eqwal Stomacare posted a profit after taxes of € 233,891 in financial year 2025.

What is the revenue of Eqwal Stomacare?

As a small company, Eqwal Stomacare is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,388,562.

How much does an employee at Eqwal Stomacare earn?

The average wage cost per full-time employee at Eqwal Stomacare was € 125,800 in 2025: staff costs of € 955,889 for 7.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Eqwal Stomacare have?

According to the 2025 annual accounts, Eqwal Stomacare has 7.6 full-time equivalents (FTE).

Eqwal Stomacare (Private Limited) - Gent - BE0849873517

Dossier Eqwal Stomacare, printed on 29 October 2026 from databakkes.be/en/0849873517/eqwal-stomacare. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Eqwal Stomacare from Gent, company number BE0849873517, closed financial year 2025 with a result of € 233,891 after tax. For that financial year Eqwal Stomacare recorded a gross margin of € 1.4 million and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 277,388 to € 233,891. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on April 22, 2026.

What it is worth Growing

€ 1.2 million

▲ 24% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 233,891

▼ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 353,071

▼ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.2 million.

People and assets in 2025

Full-time equivalents

7.6

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 955,889

▲ 6% vs 2024

€ 125,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 19,662

▼ 53% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 2,212

▼ 90% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 729,262

▲ 9% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 228,526

▼ 27% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 570,071 Gross margin 2022: € 570,071 First fiscal year in the series	€ 1,111,279 Gross margin 2023: € 1,111,279 ▲ 95% vs 2022 (€ 570,071) Favourable step	€ 1,506,145 Gross margin 2024: € 1,506,145 ▲ 36% vs 2023 (€ 1,111,279) Favourable step	€ 1,388,562 Gross margin 2025: € 1,388,562 ▼ 8% vs 2024 (€ 1,506,145) Unfavourable step	▼ 8%
Profit after taxes	€ 13,593 Profit after taxes 2022: € 13,593 First fiscal year in the series	€ 116,663 Profit after taxes 2023: € 116,663 ▲ € 103,069 vs 2022 (€ 13,593) Favourable step	€ 277,388 Profit after taxes 2024: € 277,388 ▲ 138% vs 2023 (€ 116,663) Favourable step	€ 233,891 Profit after taxes 2025: € 233,891 ▼ 16% vs 2024 (€ 277,388) Unfavourable step	▼ 16%
Equity	€ 1,090,845 Equity 2022: € 1,090,845 First fiscal year in the series	€ 1,207,508 Equity 2023: € 1,207,508 ▲ 11% vs 2022 (€ 1,090,845) Favourable step	€ 984,896 Equity 2024: € 984,896 ▼ 18% vs 2023 (€ 1,207,508) Unfavourable step	€ 1,218,787 Equity 2025: € 1,218,787 ▲ 24% vs 2024 (€ 984,896) Favourable step	▲ 24%
Total debts	€ 847,031 Total debts 2022: € 847,031 First fiscal year in the series	€ 959,469 Total debts 2023: € 959,469 ▲ 13% vs 2022 (€ 847,031) Unfavourable step	€ 1,504,105 Total debts 2024: € 1,504,105 ▲ 57% vs 2023 (€ 959,469) Unfavourable step	€ 1,460,000 Total debts 2025: € 1,460,000 ▼ 3% vs 2024 (€ 1,504,105) Favourable step	▼ 3%
Cash	€ 603,689 Cash 2022: € 603,689 First fiscal year in the series	€ 367,507 Cash 2023: € 367,507 ▼ 39% vs 2022 (€ 603,689) Unfavourable step	€ 358,383 Cash 2024: € 358,383 ▼ 2% vs 2023 (€ 367,507) Unfavourable step	€ 353,071 Cash 2025: € 353,071 ▼ 1% vs 2024 (€ 358,383) Unfavourable step	▼ 1%
Retained profit	€ 1,070,845 Retained profit 2022: € 1,070,845 First fiscal year in the series	€ 1,187,508 Retained profit 2023: € 1,187,508 ▲ 11% vs 2022 (€ 1,070,845) Favourable step	€ 964,896 Retained profit 2024: € 964,896 ▼ 19% vs 2023 (€ 1,187,508) Unfavourable step	€ 1,198,787 Retained profit 2025: € 1,198,787 ▲ 24% vs 2024 (€ 964,896) Favourable step	▲ 24%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 500,000 Dividend 2024: € 500,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 500,000) Unchanged	▼ 100%
Bank debt	€ 114,594 Bank debt 2022: € 114,594 First fiscal year in the series	€ 57,405 Bank debt 2023: € 57,405 ▼ 50% vs 2022 (€ 114,594) Favourable step	€ 23,113 Bank debt 2024: € 23,113 ▼ 60% vs 2023 (€ 57,405) Favourable step	€ 2,212 Bank debt 2025: € 2,212 ▼ 90% vs 2024 (€ 23,113) Favourable step	▼ 90%
Balance sheet total	€ 1,937,876 Balance sheet total 2022: € 1,937,876 First fiscal year in the series	€ 2,166,978 Balance sheet total 2023: € 2,166,978 ▲ 12% vs 2022 (€ 1,937,876) Unchanged	€ 2,489,002 Balance sheet total 2024: € 2,489,002 ▲ 15% vs 2023 (€ 2,166,978) Unchanged	€ 2,678,788 Balance sheet total 2025: € 2,678,788 ▲ 8% vs 2024 (€ 2,489,002) Unchanged	▲ 8%
Employees (FTE)	6.6 Employees (FTE) 2022: 6.6 First fiscal year in the series	7.9 Employees (FTE) 2023: 7.9 ▲ 1.3 vs 2022 (6.6) Unchanged	7.7 Employees (FTE) 2024: 7.7 ▼ 0.2 vs 2023 (7.9) Unchanged	7.6 Employees (FTE) 2025: 7.6 ▼ 0.1 vs 2024 (7.7) Unchanged	▼ 0.1

Key figures of Eqwal Stomacare, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to Eqwal Stomacare?

What happened at Eqwal Stomacare in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 22, 2026 New annual accounts for financial year 2025: profit of € 233,891 (▼ 16% vs 2024). Source: NBB ↗
2022 FINICOMA BV became a director. NBB
Oct 24, 2012 New establishment in Gent. KBO
Oct 18, 2012 Start of the company according to the CBE. KBO

In short

From € 13,593 profit in 2022 to € 233,891 profit in 2025.

Paid € 282,486 in corporate taxes since 2022.

Best year ever: 2024, with € 277,388 profit.

On average € 182,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

FINICOMA 100%

The stake of FINICOMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Eqwal Stomacare

Behind Eqwal Stomacare is FINICOMA BV. The shares are held by FINICOMA (100%).

Directors

According to the 2025 annual accounts

FINICOMA BV

Director · represented by Jean-Pierre Mahé

Also active at: CAROSKIN, ORTHOSHOP, DE PRETRE ORTHOPEDIE, Eqwal Charleroi, SOCIETE DISTRIBUTION MEDICALE, BASILIC ORTHO PEDIA, Aqtor!, Eqwal Care Namur +13 more

since 2022

Shareholders

FINICOMA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Herman Teirlinckstraat 15

9041 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

Eqwal same network

€ 34.5 million revenue · 2024

Eqwal Roeselare same network

€ 218,458 gross margin · 2025

FINICOMA same network

€ 2.1 million revenue · 2024

Eqwal Care same network

€ 8.5 million revenue · 2023

Nixa-Phone

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0849.873.517

VAT number

BE 0849.873.517

Registered office

Herman Teirlinckstraat 15, 9041 Gent

Names & denominations

Eqwal Stomacare

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

18 October 2012

Peppol

Active · Active since 15 Dec 2025

Activities · NACE

Activiteiten van medisch specialisten

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

Eqwal Stomacare

Financials

What happened to Eqwal Stomacare?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions